Voluntary announcement-Sihuan Pharmaceutical completed a strategic investment in canton biologics to enhance the layout of the entire industrial chain of regenerative medical aesthetics
Filed with HKEX · Stock code 460 · · 5 pages · English
Summary by 6ix AI
Sihuan Pharmaceutical Holdings Group Ltd. has completed a strategic investment in Canton Biologics to enhance its regenerative medical aesthetics business. The investment aims to secure a stable supply of core raw materials and establish an integrated industrial chain for medical aesthetics. The announcement serves to inform the investing public about the Group's latest business developments.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Sihuan Pharmaceutical Holdings Group Ltd. on 6ix
Earlier from Sihuan Pharmaceutical
- Voluntary announcement - new specifications of skin booster (brand name: dongyan) of Sihuan Pharmaceutical approved for launch by nmpa
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Notification Letter and Request Form to Non-registered Holder
- Notification Letter and Change Request Form to Registered Shareholder
- Interim Report 2026
Later from Sihuan Pharmaceutical
- Voluntary announcement - polycaprolactone microsphere facial filler for injection and hyaluronic acid sodium composite solution for injection independently developed by meiyan space, a subsidiary of Sihuan Pharmaceutical, approved for market launch in hong kong
- Voluntary announcement- phase iii clinical study data of xuanzhu biopharm's anaprazole sodium for reflux esophagitis presented at ueg week 2026
Follow Sihuan Pharmaceutical into a list and get an email when it puts out news.
Follow Sihuan Pharmaceutical